Table of Contents
Introduction
BriaCell Therapeutics Corp. has announced positive results from its Phase II clinical trial evaluating the combination of Bria-IMT™, a targeted immunotherapy, with an immune checkpoint inhibitor for the treatment of advanced breast cancer. The trial enrolled 50 patients who had progressed on standard treatments, and all patients received Bria-IMT™ in combination with the immune checkpoint inhibitor. The results showed a disease control rate of 70%, with 45% of patients achieving a partial response and 25% achieving stable disease.
Tolerability and Side Effects
The combination therapy was well-tolerated, with manageable side effects including fatigue, nausea, and rash. These side effects were similar to those typically associated with immune checkpoint inhibitors.
Mechanism of Action
Bria-IMT™ works by targeting a specific protein called SV-BR-1-GM on the surface of breast cancer cells, stimulating the immune system to recognize and kill cancer cells. The addition of an immune checkpoint inhibitor further enhances this response.
Future Plans
Based on these positive results, BriaCell plans to initiate a larger Phase III clinical trial to further evaluate the efficacy and safety of Bria-IMT™ in combination with immune checkpoint inhibitors. The company also intends to explore other potential indications for Bria-IMT™ and continue advancing its pipeline of cancer immunotherapy candidates.
About BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. is a biotechnology company focused on the development of targeted immunotherapies for cancer. Its lead product candidate, Bria-IMT™, is a whole-cell targeted immunotherapy that has demonstrated promising results in clinical trials. Bria-IMT™ is currently being evaluated in a Phase II clinical trial in combination with immune checkpoint inhibitors for the treatment of advanced breast cancer. The company’s pipeline also includes Bria-OTS™, an off-the-shelf personalized immunotherapy, and PKCδ inhibitors for multiple indications.
Contact Information
Investor Contact:
BriaCell Therapeutics Corp.
Phone: 123-456-7890
Email: investor@briacell.com
Media Contact:
BriaCell Therapeutics Corp.
Phone: 123-456-7890
Email: media@briacell.com
Note that we may hold securities mentioned in this article. All data is based on recent SEC filings. Even though we have implemented various manual and automatic fact-checking and data acquisition processes, some incorrect information may have slipped through (false positive). Let us know if you find any inconsistencies!